Patents by Inventor Patrick Arbuthnot

Patrick Arbuthnot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140350080
    Abstract: This invention relates to modified short interfering RNA (siRNA) nucleic acid molecules, particularly siRNA's which have been modified by the addition of a 2-0-guanidinopropyl (GP) modified nucleoside. In particular the invention relates to modified siRNAs which are capable of silencing target sequences, methods of treating and preventing infection by using the siRNAs, medicaments containing the siRNAs and use of the siRNAs.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 27, 2014
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Patrick Arbuthnot, Justin Hean, Abdullah Ely, Musa Marimani, Jolanta Brzezinska, Jennifer D'Onofrio, Maximilian C.R. Buff, Joachim W. Engels, Stefan Bernhardt
  • Patent number: 8293974
    Abstract: A DNA polynucleotide is described herein having a modified sequence of a target gene, wherein any one type of nucleotide in the target gene sequence has been chemically modified to another type of nucleotide; and a complementary sequence of the unmodified target gene; wherein either one of the modified sequence or the complementary sequence is in a reverse orientation to the other sequence; and wherein the RNA sequence transcribed from the DNA polynucleotide forms a duplex between the modified sequence and the complementary sequence so that a long double stranded RNA (IdsRNA) duplex forms between the modified and complementary sequences with base pair mismatches where the nucleotides have been modified, the IdsRNA duplex being capable of inhibiting expression of the target gene. RNA polynucleotides and IdsRNA duplexes transcribed by the DNA polynucleotide are also described, as is a method for producing the IdsRNA duplexes. These IdsRNA duplexes can be used in gene silencing.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: October 23, 2012
    Assignee: University of Witwatersrand
    Inventors: Patrick Arbuthnot, Marc Saul Weinberg, Marie Emma Christine Rey, Johan Harmse, Sarah Helen Taylor
  • Publication number: 20100297023
    Abstract: The present invention provides a lipid of the formula (I) R3R4N—[Y]q—(CpH2p)—X-Linker-NR1R2 (I) wherein R3 and R4 are independently selected from H and hydrocarbyl groups; q is an integer selected from 1 to 10; Y represents a group (CnH2n)NR5, wherein (i) when q is 1, n is 2, or (ii) when q is greater than 1, each Y may be the same or different and each n is an integer independently selected from 1 to 10, with the proviso that for at least one unit Y, n is 2, and (iii) each R5 is independently selected from H and hydrocarbyl groups; p is an integer selected from 1 to 10; X is an optional group selected from —NR7—, —C(?O)—NR8—, —NR9—C(?O)—, —C(?O)—, —O—, and NR10—C(=0)0-, wherein each R7, R8, R9 and R10 is independently selected from H and hydrocarbyl groups, Linker is an optional group selected from amino acid residues, peptide residues and groups of the formula —(OCH2CH2)1-10, —NR6-(CvH2v)—C(?O)—, wherein R6 is H or a hydrocarbyl group and v is an integer selected from 1 to 11, and —C(=0)-(CH2)0-10—CH2—C(=0)
    Type: Application
    Filed: December 21, 2007
    Publication date: November 25, 2010
    Inventors: Andrew David Miller, Patrick Arbuthnot, Michael Jorgensen, Michael Keller, Nazila Kamaly, Abderrahim Aissaoui, Maya Thanou
  • Publication number: 20100184840
    Abstract: This invention relates to inhibition of hepatitis gene expression. More specifically, the invention relates to a method of using RNA sequences to inhibit Hepatitis B and C Virus replication. Expression cassettes that include DNA sequences derived from endogenous micro RNAs (miRs) are used in the method and are transcribed by Pol II promoters, and then processed to generate sequences that are specific to target hepatitis virus sequences (RNAi effecter sequences). The RNAi effecter sequences can target the selected hepatitis virus sequences resulting in gene silencing or transcriptional inhibition of the hepatitis virus gene. The expression cassettes may be delivered in vitro or in vivo to host cells. A pharmaceutical composition containing the expression cassettes is also claimed.
    Type: Application
    Filed: November 30, 2009
    Publication date: July 22, 2010
    Applicant: University of the Witwatersrand
    Inventors: Patrick Arbuthnot, Abdullah Ely, Tanusha Naidoo, Marc Saul Weinberg, Victoria Mary Longshaw
  • Publication number: 20100152282
    Abstract: A DNA polynucleotide is described herein having a modified sequence of a target gene, wherein any one type of nucleotide in the target gene sequence has been chemically modified to another type of nucleotide; and a complementary sequence of the unmodified target gene; wherein either one of the modified sequence or the complementary sequence is in a reverse orientation to the other sequence; and wherein the RNA sequence transcribed from the DNA polynucleotide forms a duplex between the modified sequence and the complementary sequence so that a long double stranded RNA (IdsRNA) duplex forms between the modified and complementary sequences with base pair mismatches where the nucleotides have been modified, the IdsRNA duplex being capable of inhibiting expression of the target gene. RNA polynucleotides and IdsRNA duplexes transcribed by the DNA polynucleotide are also described, as is a method for producing the IdsRNA duplexes. These IdsRNA duplexes can be used in gene silencing.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 17, 2010
    Applicant: University of the Witwatersrand
    Inventors: Patrick Arbuthnot, Marc Saul Weinberg, Marie Emma Christine Rey, Johan Harmse, Sarah Helen Taylor
  • Publication number: 20080207539
    Abstract: The invention provides a self-processing RNA expression cassette which includes at least one pair of processing units, an RNAi effecter sequence of predetermined length that regulates target gene expression which is flanked by said pair of processing units; and at least one pair of cognate ribozyme cis-cleavage target sites located 5? and 3? of the RNAi effecter sequence. The self-processing RNA expression cassette is able to express in vivo and in vitro and the RNAi effecter sequence includes at least one target recognition sequence derived from the Hepatitis B Virus (HBV) X gene (HBx).
    Type: Application
    Filed: August 31, 2004
    Publication date: August 28, 2008
    Inventors: Patrick Arbuthnot, Marc Weinberg, Sergio Catril Carmona, Ely Abdullah